BioVie (BIVI) vs CytoMed Therapeutics (GDTC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
BioVie (BIVI) has outperformed CytoMed Therapeutics (GDTC) over the past year, losing 35.0% versus a loss of 56.5%. BioVie is the larger company by market cap ($11.4 million vs $11.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIVI | GDTC |
|---|---|---|
| Share price | $1.31 | $0.9385 |
| Market cap | $11.37M | $11.20M |
| 1-day change | +2.34% | -0.68% |
| YTD return | +10.34% | -29.22% |
| 1-year return | -35.03% | -56.46% |
| 5-year return | -99.78% | — |
| EPS (TTM) | $-3.05 | $-0.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.79 | $3.68 |
| 52-week low | $0.82 | $0.68 |
| Distance from 52-week high | -65.44% | -74.50% |
| Analyst consensus | none | none |
| Avg. price target upside | +301.53% | +343.26% |
| Average volume | 4.60M | 78.66K |
| Shares outstanding | 8.68M | 11.93M |
| Employees | 13 | 42 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BIVI has outperformed GDTC by 21.4 percentage points over the past year.
About BioVie
BIVI stock →BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
About CytoMed Therapeutics
GDTC stock →CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.
Health Care · Biotechnology: Pharmaceutical Preparations · 42 employees
BIVI vs GDTC FAQ
Which is bigger, BioVie or CytoMed Therapeutics?
BioVie (BIVI) is larger, with a market capitalization of $11.37M compared with $11.20M for CytoMed Therapeutics (GDTC).
Which stock has performed better over the past year, BIVI or GDTC?
BIVI returned -35.03% over the past 12 months, compared with -56.46% for GDTC (price return, excluding dividends). Past performance does not predict future results.
Are BioVie and CytoMed Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.